The Effect of Antiviral Therapy With Pegylated Interferon-alpha on Auditory Disability
NCT01265693 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2018-07-24
Summary
The aim of the study is to assess the effect of antiviral therapy with pegylated interferon alpha for hepatitis C and B on auditory disability as there are reports in the English literature on auditory disability caused by interferon alpha.
Conditions
- Hearing Loss
- Sudden Deafness
Sponsors & Collaborators
-
Carmel Medical Center
lead OTHER
Principal Investigators
-
Eli Zuckerman, M.D. · Liver Unit, Carmel Medical Center
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-01-09
- Primary Completion
- 2015-03-31
- Completion
- 2015-03-26
Countries
- Israel
Study Locations
More Related Trials
-
Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
NCT00408304 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of HIV and Hepatitis C Virus on the Brain
NCT00494936 ·Status: COMPLETED
-
Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy
NCT01120795 ·Status: COMPLETED ·Phase: PHASE4
-
Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy
NCT02469012 ·Status: UNKNOWN ·Phase: NA
-
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
NCT00788918 ·Status: COMPLETED ·Phase: NA
-
Treatment of Hepatitis C in Psychiatric Patients
NCT00751426 ·Status: COMPLETED
-
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
NCT00136214 ·Status: COMPLETED
-
HCV Treatment Initiation During Acute Psychiatric Admission
NCT04625322 ·Status: UNKNOWN ·Phase: PHASE4
-
VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients
NCT00108563 ·Status: COMPLETED ·Phase: PHASE4
-
P300 in Early Cognitive Impairment in Hepatitis C Virus
NCT04389268 ·Status: COMPLETED
-
Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents
NCT03894696 ·Status: UNKNOWN
-
Hepatitis C Pharmacy-based Strategy for Injectors
NCT04698629 ·Status: COMPLETED
-
Pharmacist-led Hepatitis C Management
NCT04322981 ·Status: UNKNOWN ·Phase: PHASE4
-
Expression of Inflammasomes in HCV Patients
NCT04244383 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
NCT03413696 ·Status: COMPLETED
-
Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)
NCT00723892 ·Status: COMPLETED
-
A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers
NCT04366973 ·Status: COMPLETED
-
Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication
NCT00188201 ·Status: UNKNOWN
-
Hepatitis C Translating Initiatives for Depression Into Effective Solutions
NCT01143896 ·Status: COMPLETED ·Phase: NA
-
Transforming the Cascade Of Hepatitis C Care
NCT03226509 ·Status: COMPLETED
-
Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs
NCT03170076 ·Status: UNKNOWN
-
Hepatitis C Treatment and Atherosclerosis
NCT00659256 ·Status: COMPLETED
-
Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C
NCT01465919 ·Status: TERMINATED ·Phase: PHASE4
-
the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac Function
NCT03166943 ·Status: UNKNOWN ·Phase: NA
-
Hepatitis C Self-Management
NCT00328042 ·Status: COMPLETED ·Phase: NA